Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel

JAMA

Volumn 280, Issue 1, 1998, Pages 78-86

  Carpenter, Charles C J ^a,n   Fischl, Margaret A ^b   Hammer, Scott M ^c   Hirsch, Martin S ^c   Jacobsen, Donna M ^d   Katzenstein, David A ^e   Montaner, Julio S G ^f   Richman, Douglas D ^g   Saag, Michael S ^h   Schooley, Robert T ⁱ   Thompson, Melanie A ^j   Vella, Stefano ^k   Yeni, Patrick G ^l   Volberding, Paul A ^m  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d International AIDS Society USA   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j AIDS Research Consortium of Atlanta   (United States)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l BICHAT HOSPITAL   (France)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL PROTOCOL; DRUG CHOICE; DRUG POTENCY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VIRUS DETECTION;

EID: 0007010412     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.1.78     Document Type: Review

References (108)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146-154.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
3. + lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in HIV-1 infection. Nature. 1995;373:117-122.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
6. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;387:188-191.
7. Wong JK, Hezareh M, Gunthard H, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278: 1291-1295.
8. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
9. Chun T, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197.
10. Montaner JSG, Harris M, Mo T, Harrigan PR. Suppression of plasma viral load below 20 copies/ mL is needed to achieve a long-term virologic response. AIDS. In press.
11. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
12. Montaner J, DeMasi R, Hill A, et al. Validation of HIV-1 RNA and CD4 count as surrogate markers in the CAESAR trial. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection; October 11-15, 1997; Hamburg, Germany. Abstract 207.
13. Raboud JM, Montaner JSG, Rae S, et al. Predictors of duration of plasma viral load suppression. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract A-14.
14. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
15. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
16. Chiasson MA, Berenson L, Li W, et al. Accelerating decline in New York City AIDS mortality. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 9b.
17. Reggy A, Wong T, Chiasson M, Simonds R, Loo V, Heffess J. Protease inhibitors and declining AIDS deaths in New York City. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract LB7.
18. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998; 279:450-454.
19. Katlama C, Valantin MA, Calvez V, et al. ALTIS PLUS: Long-term d4T-3TC with and without ritonavir. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 376.
20. Anis AH, Hogg RS, Yip B, et al. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women. Pharmacoeconomics. 1998;13:327-336.
21. McCollum M, Klaus B, La Rue R, Bessessen M. HAART reduced overall costs of HIV care at DVAMC-Denver. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 200.
22. Raffi F, Pialoux G, Brun-Vezinet F, et al. Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine, lamivudine, and indinavir. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract LB15.
23. Havlir DV, Hirsch M, Collier A, et al. Randomized trial of indinavir vs zidovudine/lamivudine vs indinavir/zidovudine/lamivudine maintenance therapy after induction of indinavir/zidovudine/ lamivudine therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract LB16.
24. Hsu A, Granneman GR, Japour A, et al. Evaluation of potential ritonavir and indinavir combination bid regimens. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract A-57.
25. McCrea J, Buss N, Stone J, et al. Indinavirsaquinavir single dose pharmacokinetic study. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 608.
26. Buss N, and the Fortovase® Study Group. Saquinavir soft gel capsule (Fortovase®) pharmacokinetics and drug interactions. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 354.
27. Squires K, Riddler S, Havlir D, et al. Coadministration of indinavir and nelfinavir without RTIs in a twice daily regimen: preliminary safety, pharmacokinetic and antiviral activity results. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection; October 11-15, 1997; Hamburg, Germany. Abstract 924.
28. Yuen G, Kerr B, Lee C, et al. Overview of invitro and in-vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC.
29. Sadler BM, Eron J, Wakeford J, et al. Pharmacokinetics of 141 W94 and indinavir after single dose coadministration in HIV-positive volunteers. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract A-56.
30. Murphy R, Gagnier P, Lamson M, Dusek A, Ju W, Hsu A. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC.
31. Ferry JJ, Herman BD, Cox SR, Carlson GF, Carberry PA. Delavirdine and indinavir: a pharmacokinetic drug-drug interaction study in healthy adult volunteers. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC.
32. Ferry JJ, Schneck DW, Carlson GF, et al. Evaluation of the pharmacokinetic interaction between ritonavir and delavirdine in healthy volunteers. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC.
33. Shelton M, Hewitt RG, Adams JM, et al. Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract A-63.
34. Kravcik S, Sahai H, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft-gel capsule exposure in HIV-positive patients. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 371.
35. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir and nevirapine. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 614.
36. Skowron G, Leoung G, Dusek A, et al. Stavudine, nelfinavir and nevirapine: preliminary safety, activity and pharmacokinetic interactions. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 350.
37. Cox SR, Schneck DW, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug-drug interaction study in healthy adult volunteers. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 345.
38. Fiske WD, Benedek EH, White SJ, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate in healthy volunteers. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract I-174.
39. Fiske WD, Benedek EH, White SJ, Peperess KA, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 349.
40. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 372.
41. Posniak A. Study of protease inhibitors in combination in Europe (SPICE). In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection; October 11-15, 1997; Hamburg, Germany. Abstract 209.
42. Zorrilla C, Clark R, Currier J, et al. Women first: a study in HIV positive women of quadruple therapy: nelfinavir (NFV), saquinavir (SQV), stavudine (d4T) and lamivudine (3TC). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 722.
43. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47(RR-05):43-82.
44. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126:946-954.
45. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177: 40-47.
46. Chesney M, Ickovics J, for the Recruitment, Adherence and Retention Committee of the ACTG (1997). Adherence to combination therapy in AIDS clinical trials (1997). Paper presented at: the Annual Meeting of the AIDS Clinical Trials Group; July 22, 1997; Washington, DC.
47. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
48. + cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
49. + cells per cubic millimeter. N Engl J Med. 1996;335:1091-1098.
50. Meduri GU, Stover DE, Greeno RA, Nash T, Zaman MB. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections. Chest. 1991;100:1272-1276.
51. Welles SL, Jackson JB, Yen-Lieberman B. Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J Infect Dis. 1996;174:696-703.
52. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349:1413-1421.
53. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nueleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
54. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
55. 3 - 60 week follow-up. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 383.
56. Sension M, Farthing C, Palmer-Pattison T, Pilson R, Siemon-Hryczyk P. Fortovase (saquinavir soft gel capsule) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 369.
57. Borleffs JC, the CHEESE Study Team. First comparative study of saquinavir soft gel capsules vs indinavir as part of triple therapy regimen (CHEESE). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 387b.
58. Slater L, and the NV15355 Study Group. Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naive patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 368.
59. Start I, Squires K, Gulick R, et al. An open-label, randomized, comparative study of d4T + 3TC + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 380.
60. Villalba N, Gomez-Cano M, Casas E, Mas A, Soriano V, Gonzalez-Lahoz J. Antiviral activity and acceptance of two different triple combinations: d4T + indinavir + 3TC vs. d4T + indinavir + ddI. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 378.
61. Connick E, Lederman M, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract LB14.
62. Opravil M, Pennekamp A, Huber W, et al. EARTH study: AZT + 3TC vs. AZT + 3TC + ritonavir in asymptomatic patients with early HIV infection. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1998; Toronto, Ontario. Abstract 1-94.
63. Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the VIRACEPT 511 protocol using 3 HIV-RNA assays. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 372.
64. Clumeck N, and the AVANTI Study Group. AVANTI 3: a randomised, double-blind, comparative trial to evaluate the efficacy, safety, and tolerance of AZT/3TC vs. AZT/3TC/nelfinavir in antiretroviral naive patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 8.
65. Pedneault L, Elion R, Adler M, et al. Stavudine, didanosine, and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1998; Washington, DC. Abstract 241.
66. Goebel F. AVANTI 2: a randomized, double blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC/indinavir in antiretroviral naive patients. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection; October 11-15, 1997; Hamburg, Germany. Abstract 211.
67. Gulick R, Mellors J, Havlir D, et al. Indinavir, zidovudine, and lamivudine: concurrent or sequential therapy in zidovudine-experienced patients. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario.
68. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998; 279:930-937.
69. Staszewski S, Morales-Ramirez J, Tashima K, et al. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir, versus efavirenz + zidovudine + lamivudine, versus indinavir + zidovudine + lamivudine. Paper presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, Ill. Abstract 5.
70. Vella S, Floridia M, Tomino C, et al. A triple combination of reverse transcriptase inhibitors (2 nRTIs plus 1 NNRTI) induces a pronounced and sustained effect on RNAand CD4 in antiretroviral-naive patients with very advanced disease (Trial 155047). In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract LB7.
71. Kaspar R, Werntz G, DuBois DB. Early results of combined stavudine, lamivudine, and nevirapine: a twice daily, well-tolerated, protease inhibitor-sparing regimen for the treatment of HIV-1 infection. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 696.
72. Sargent S, Green S, Para M, et al. Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with rescriptor + retrovir + epivir. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 699.
73. Montaner J, Reiss P, Cooper D, et al, for the INCAS Study Group. Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 695.
74. Gisolf E, Colebunders R, Van Wanzeele F, et al. Treatment with ritonavir/saquinavir versus ritonavir/saquinavir/stavudine. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 389.
75. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two of follow-up. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 388.
76. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 393.
77. DeWolf F, Lukashov VV, Danner SA, Goudsmit J, Lange JMA. Clearance of HIV-1 following treatment with three, four, and five anti-HIV drugs. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 384.
78. Gallant JE, Heath-Chiozzi M, Raines C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 394a.
79. Kravcik S, Farnsworth A, Patick A, et al. Long-term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 394c.
80. Opravil M, for the SPICE Study Team. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 394b.
81. Kahn J, Mayers D, Riddler S, et al. Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP266) in combination with indinavir (IDV): suppression to "<1 copy/mL" (OD = background) by Amplicor® as a predictor of virologic treatment response [DMP 266-003. Cohort IV]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 692.
82. Polis MA, Schrager L, Yoder C, et al. Virologic, immunologic, and histologic responses to a 4-drug combination therapy in antiretroviral naive HIV-infected persons. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 394.
83. Skowron G, Myers M, Pedneault L, Smiley M, Warburg M, Odoriso M. A protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with zidovudine and didanosine with or without lamivudine or nevirapine for the treatment of HIV infection. In: Program and abstracts of the 37th Interscienee Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1998; Toronto, Ontario. Abstract 1-95.
84. Lafeuillade A, Poggi C, Djediouane A, Chollet C, Profizi N, Sayada C. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection. Antiviral Ther. 1997;2:219-227.
85. Staszewski S, Katlama C, Harrer T, et al. Preliminary long-term open-label data from patients using abacavir (1592) containing, antiretroviral treatment regimens. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 658.
86. Sommadossi JP, Zhou X, Moore J, et al. Impairment of stavudine phosphorylation in patients receiving a combination of zidovudine and stavudine. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 3.
87. Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of viracept in combination with stavudine and lamivudine. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 373.
88. Sension M, Elion R, Farthing C, Currier J, Lindquist C, Richardson B. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept combined with nRTIs in HIV-infected treatment naive patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 387A.
89. Gunthard H, Wong J, Ignacio C, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
90. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in HIV infection of adults: implications for clinical management. JAMA. 1998;279:1984-1991.
91. - cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART), Swiss HIV Cohort Study. Lancet. 1998;351:723-724.
92. Philips P, Zala C, Rouleau D, Montaner JSG. Mycobacterial lymphadenitis: can highly active antiretroviral therapy unmask subclinical infection? In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 351.
93. Race E, Adelson-Mitty J, Barlam T, Japour A. Focal inflammatory lymphadenitis and fever following initiation of protease inhibitor in patients with advanced HIV-1 disease. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 352.
94. Lipsky J. Abnormal fat accumulation in patients with HIV-1 infection. Lancet. 1998;351:847-848.
95. Lo JC, Mulligan K, Tal VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
96. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
97. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PIs). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 410.
98. Sommadossi JP, Valantin MA, Zhou X, et al. Intracellular phosphorylation of stavudine and lamivudine correlates with their antiviral activity in naive and zidovudine-experienced HIV-infected patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 362.
99. Tebas P, Kane E, Klebert M, Simpson J, Powderly WG, Henry K. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. February 1-5, 1998; Chicago, Ill. Abstract 510.
100. Montaner JSG, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis. 1997;175:801-806.
101. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994;266:801-805.
102. + T cell responses associated with control of viremia. Science. 1997; 278:1447-1450.
103. Lori F, Jessen H, Clerici M, et al. Drugs suppressing HIV replication and cell proliferation decrease proviral DNA to undetectable levels. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract LB11.
104. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47(RR-02):1-30.
105. Fiscus SA, Adimora AA, Schoenbach VJ. Importance of maternal ZDV therapy in the reduction of perinatal transmission of HIV. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 176.
106. Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:145-152.
107. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47(RR-7):1-33.
108. Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med. 1998;128:306-312.